Audentes Therapeutics (BOLD)

24.30 +0.39 (1.63%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (3/8/19 *Est.)

Latest Headlines

Form SC 13G/A Audentes Therapeutics, Filed by: Partner Fund Management, L.P. February 14, 2019 5:26 PM - SEC Filing Form SC 13G Audentes Therapeutics, Filed by: Redmile Group, LLC February 14, 2019 4:16 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/ February 14, 2019 2:09 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: 5AM VENTURES III, L.P. February 13, 2019 4:23 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: FMR LLC February 13, 2019 11:50 AM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: ORBIMED ADVISORS LLC February 13, 2019 6:14 AM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP February 12, 2019 9:43 AM - SEC Filing Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 8, 2019 6:00 PM - PR NewsWire Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Patterson Matthew R February 8, 2019 5:51 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Soloway Thomas P February 8, 2019 5:30 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Smith Julie February 8, 2019 5:29 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Schuetz Thomas J. February 8, 2019 5:28 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: PRASAD SUYASH February 8, 2019 5:26 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Morrison Scott W February 8, 2019 5:25 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: LANGE LOUIS G February 8, 2019 5:23 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Jarrett Jennifer February 8, 2019 5:23 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Holles Natalie C. February 8, 2019 5:22 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Goldberg Mark Alan February 8, 2019 5:21 PM - SEC Filing Form SC 13G Audentes Therapeutics, Filed by: BlackRock Inc. February 8, 2019 6:14 AM - SEC Filing Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation January 31, 2019 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Jan 24 Filed by: Holles Natalie C. January 25, 2019 7:29 PM - SEC Filing Guggenheim Upgrades Audentes Therapeutics (BOLD) to Buy January 11, 2019 6:55 AM - StreetInsider Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities January 7, 2019 8:00 AM - PR NewsWire Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 4, 2019 6:00 PM - PR NewsWire Form 4 Audentes Therapeutics, For: Jan 03 Filed by: Mosbrooker Eric January 4, 2019 4:49 PM - SEC Filing Form 3 Audentes Therapeutics, For: Jan 03 Filed by: Mosbrooker Eric January 4, 2019 4:48 PM - SEC Filing Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer January 3, 2019 8:00 AM - PR NewsWire Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference January 2, 2019 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Dec 24 Filed by: LANGE LOUIS G December 27, 2018 5:44 PM - SEC Filing Form 4 Audentes Therapeutics, For: Dec 06 Filed by: Patterson Matthew R December 10, 2018 4:40 PM - SEC Filing Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 7, 2018 6:00 PM - PR NewsWire JPMorgan Starts Audentes Therapeutics (BOLD) at Overweight November 26, 2018 3:52 AM - StreetInsider Full Article List